SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is surging after a preliminary business update revealed record-breaking demand, with over $60 billion in new orders and significantly higher gross margins than previously guided. The community is actively discussing the potential for a massive short squeeze, as investors weigh these strong order figures against lingering concerns regarding management and historical accounting scrutiny.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance faces a critical juncture as the planned merger with Warner Bros. Discovery encounters aggressive regulatory scrutiny and potential litigation from U.S. state attorneys general. While investors are debating whether the consolidation is a necessary evolution for media survival or a value-destructive move, the stock remains a focal point for the community due to the looming threat of significant financial penalties and legal delays.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund (USO) is trending as escalating military conflicts between the U.S. and Iran create significant supply chain uncertainty, particularly surrounding crucial transit routes in the Middle East. Market participants are actively debating the impact of these geopolitical tensions on inflation, while monitoring reports of naval blockades and military strikes that keep energy prices elevated.

Occidental Petroleum Corp. engages in the exploration and production of oil and natural gas. It operates through the following segments: Oil and Gas, Chemical, and Midstream and Marketing. The Oil and Gas segment explores for, develops and produces oil and condensate, natural gas liquids, and natural gas. The Chemical segment manufactures and markets basic chemicals and vinyls. The Midstream and Marketing segment purchases, markets, gathers, processes, transports and stores oil, condensate, natural gas liquids, natural gas, carbon dioxide, and power. The company was founded in 1920 and is headquartered in Houston, TX.

Occidental Petroleum Corp.

Occidental Petroleum is capturing significant investor attention as escalating geopolitical tensions in the Middle East and ongoing supply risks in the Strait of Hormuz keep oil prices elevated. The community remains focused on the company's strong cash flow and debt reduction potential, with traders closely debating the sustainability of current energy prices amid persistent headline-driven volatility.

Duolingo, Inc. is a language-learning website and mobile application, which engages in the development of a free language learning website and crowd sourced text translation platform. It offers Duolingo for Schools, a free, web-based tool that aims to make it easier for teachers to use the Duolingo platform in a structured learning environment, and English Test, an online, on-demand assessment of English proficiency. The company was founded by Luis von Ahn and Severin Hacker in 2011 and is headquartered in Pittsburgh, PA.

Duolingo Inc - Ordinary Shares - Class A

Duolingo Inc

Duolingo is seeing intense market volatility and community debate as investors weigh strong user engagement metrics and debt-free fundamentals against concerns regarding slowing booking growth and long-term competitive threats from AI. While bulls highlight the company's strong cash flow and potential for AI-driven monetization, the stock remains a focal point for short sellers and momentum traders navigating significant valuation compression.

Venture Global, Inc. engages in the provision of United States liquefied natural gas sourced from resource rich North American natural gas basins. It operates through the following segments: Calcasieu Project, Plaquemines Project, CP2 Project, and Sales and shipping. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global is trending as investors weigh strong operational fundamentals, such as a major jump in liquefaction fees and robust EBITDA growth forecasts, against ongoing geopolitical instability in the Strait of Hormuz that continues to impact energy supply chains. Community sentiment remains polarized between long-term bulls focusing on the company's export capacity and infrastructure expansion, and frustrated traders pointing to high-frequency trading suppression and recurring volatility linked to Middle East conflict headlines.

Cardano is a blockchain platform built on academic research that enables smart contracts and decentralized applications while using significantly less energy than traditional cryptocurrencies like Bitcoin.   What sets Cardano apart is its methodical, research-driven approach — every major feature is peer-reviewed by scientists and cryptographers before being added to the network. This careful process aims to create a more secure and stable foundation compared to platforms that prioritize speed over thorough testing. The platform's native cryptocurrency, ADA, is used to send money, pay transaction fees, and participate in network governance.  Cardano uses a proof-of-stake system to process transactions, which works differently from Bitcoin's mining approach. Instead of competing to solve complex puzzles, users can "stake" their ADA — essentially locking it up temporarily — to become validators who verify transactions. The system selects validators based on how much ADA they've staked and for how long, then rewards them with additional ADA for their participation. This approach uses far less energy than traditional mining while keeping the network secure. The platform also features a two-layer design that separates basic payment transactions from smart contract operations, allowing each function to be optimized independently for better performance.   ADA holders can earn staking rewards by locking up their tokens to help secure the network, vote on proposed changes to the platform, and use ADA for international money transfers with lower fees than traditional services.  Cardano was founded in 2017 by Charles Hoskinson, who previously helped create Ethereum. Hoskinson leads Input Output Global (IOG), the technology company that builds and maintains Cardano's core software. The ecosystem operates through three organizations: IOG handles technical development, the Cardano Foundation promotes adoption and standardization, and Emurgo helps businesses integrate blockchain technology into their operations. This structure distributes responsibilities across multiple groups rather than concentrating control in a single entity.   In February 2025, major asset manager Grayscale Investments filed to create an exchange-traded fund (ETF) for Cardano with the U.S. Securities and Exchange Commission, which would allow traditional investors to buy ADA through their regular brokerage accounts without needing to set up cryptocurrency wallets.

Cardano

Cardano ($ADA.X) is currently experiencing high community polarization, with many investors debating whether to buy the dip following a sharp price decline or to exit entirely due to perceived lack of project progress and concerns over founder leadership. While some holders highlight potential upside from technical network upgrades and optimistic long-term accumulation strategies, skeptics are actively labeling the asset a scam and pointing to poor adoption metrics compared to other top-tier blockchains.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel Corp is experiencing intense volatility and heightened community debate as investors weigh ongoing restructuring, including data center job cuts, against its foundry expansion strategy ahead of earnings. While some traders view the recent price retracement as a buying opportunity, others are cautious of potential downside, leading to active discussions about institutional manipulation and the company's long-term ability to compete in the semiconductor space.

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovance Biotherapeutics is trending as institutional accumulation and heavy trading volume drive the stock toward the psychologically significant five-dollar level, with community members actively discussing a potential short squeeze fueled by high short interest. Investors are keenly focused on anticipation of the second-quarter earnings report and upcoming clinical milestones, viewing the current price action as a de-risking phase for a company that has successfully moved into a commercial-stage pipeline.

Nokia Oyj engages in the provision of network infrastructure, technology, and software services. It operates through the following segments: Mobile Networks, Network Infrastructure, Cloud and Network Services, and Nokia Technologies. The Mobile Networks segment offers technologies for Radio Access Networks (RAN) as well as Microwave Radio Links (MWR) for transport networks. The Network Infrastructure serves communication service providers, enterprises, webscales and public sector customers. The Cloud and Network Services segment builds around software and the cloud and is focused on driving leadership in cloud-native software and as-a-service delivery models, as demand for critical networks accelerates; and with strong market positions in communications software, private wireless networks, and cognitive (or intelligent) services. The Nokia Technologies segment, building on decades of innovation and R&D leadership in technologies used in virtually all mobile devices used today, is expanding the Nokia patent licensing business, reintroducing the Nokia brand to smartphones through brand licensing, and establishing a technology licensing business. The company was founded by Fredrik Idestam in 1865 and is headquartered in Espoo, Finland.

Nokia Corp - ADR

Nokia Corp

Nokia is trending as retail investors weigh the company's recent partnership with NVIDIA on AI-RAN infrastructure against significant selling pressure that has dragged shares to multi-year support levels. The community remains sharply divided, with bulls aggressively accumulating shares ahead of earnings in anticipation of a technical rebound, while skeptics warn of further downside risks following recent market volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

All You Need to Know About Immix Biopharma (IMMX) Rating Upgrade to Buy

Immix Biopharma (IMMX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Immix Biopharma Analyst Bullish But Flags Safety, Adoption Questions

BofA Securities initiates Immix Biopharma with Buy rating, citing NXC-201's potential in AL amyloidosis and peak sales near $963 million.read more...

Wall Street Analysts Think Immix Biopharma (IMMX) Could Surge 113.58%: Read This Before Placing a Bet

The consensus price target hints at an 113.6% upside potential for Immix Biopharma (IMMX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts See a 120.59% Upside in Immix Biopharma (IMMX): Can the Stock Really Move This High?

The consensus price target hints at a 120.6% upside potential for Immix Biopharma (IMMX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

What's Going On With Immix Biopharma Stock Thursday?

Immix Biopharma (IMMX) prices $150M public offering to fund its NXC-201 cell therapy into mid-2028. Read the details.read more...

The Biotech Repricing Wave May Be Starting as Capital Pours into High-Impact Oncology Platforms

Biotech investors are once again rotating aggressively into clinical-stage growth stories as a fresh wave of capital raises, pipeline expansions, analyst initiations, and oncology breakthroughs reshapes momentum across the sector. $NTHI, $IMMX, $RLAY, $AKTX, $LIMN

Immix Biopharma (NASDAQ:IMMX) Trading Down 4.6%  - Time to Sell?

Immix Biopharma (NASDAQ:IMMX) Shares Down 4.6% - Time to Sell...

Immix Biopharma (NASDAQ:IMMX) Trading 12% Higher - Should You Buy?

Immix Biopharma (NASDAQ:IMMX) Stock Price Up 12% - Still a Buy...

Immix Biopharma, Inc. (NASDAQ:IMMX) Receives Average Rating of "Moderate Buy" from Brokerages

Immix Biopharma, Inc. (NASDAQ:IMMX - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the six brokerages that are currently covering the stock, MarketBeat reports. One...

Immix Biopharma (NASDAQ:IMMX) Stock Price Expected to Rise, Mizuho Analyst Says

Mizuho raised their target price on shares of Immix Biopharma from $14.00 to $15.00 and gave the company an "outperform" rating in a research note on Monday...

Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company was founded by Ilya Rachman, Sean Senn, and Vladimir Torchilin in 2012 and is headquartered in Los Angeles, CA.

Immix Biopharma Inc

 Nasdaq, S&P 500 Futures Rise Ahead Of Fed Decision This Week: Why NFLX, CFLT, BA, LLY, IMMX Are On Traders' Radar

Equity

Extremely Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$9.57
Prev Close	$8.80
Open	$8.92
Dividend Yield	0.00%
50-Day Moving Average	$9.49
Beta	1.23
Avg. Volume	2.02M
PE Ratio	-10.40

52-Week High	$12.14
52-Week Low	$1.94
Market Capitalization	$626.47M
EPS (Annual)	-$0.893
Price to Book	6.01
Revenue Per Employee	$0.00

Feed

News

Sentiment

Fundamentals

Info

IMMXImmix Biopharma Inc

Latest IMMX News